{"entity":{"id":"hemogenyx-pharmaceuticals","kind":"company","name":"Hemogenyx Pharmaceuticals","aka":["Hemogenyx Pharmaceuticals plc"],"tldr":"Hemogenyx Pharmaceuticals is developing a CAR-T cell therapy, a patient's own immune cells engineered to attack cancer, aimed at the FLT3 protein on acute myeloid leukaemia cells. It is in a first trial at MD Anderson for leukaemia that has come back or stopped responding.","summary":"Hemogenyx Pharmaceuticals plc is listed on the London Stock Exchange (HEMO) and headquartered at 6 Heddon Street, London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, at a research facility on Amsterdam Avenue, New York. The company was incorporated in England and Wales on 13 February 2013 and admitted to the LSE on 5 October 2017, according to the company. HG-CT-1 (HEMO-CAR-T) is an autologous third-generation CAR-T using a proprietary humanised anti-FLT3 scFv that the company says does not compete with FLT3 ligand; a phase 1 study in relapsed or refractory AML at MD Anderson Cancer Center is registered (NCT06786533), and the company's pipeline page reported two patients dosed and a third recruited. A preclinical FLT3 x CD3 bispecific antibody (CDX) is also in development, with stated potential for bone marrow transplant conditioning. Its first registered cancer trial, NCT06786533, was posted on ClinicalTrials.gov in January 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://hemogenyx.com/"},{"label":"Pipeline","url":"https://hemogenyx.com/pipeline/"},{"label":"ClinicalTrials.gov: phase 1 trial of anti-FLT3 CAR-T cells in relapsed or refractory AML (NCT06786533)","url":"https://clinicaltrials.gov/study/NCT06786533"}],"tags":[],"related":[],"cancers":["aml"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","bispecific-antibody"],"targets":["flt3","cd3"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Read on 29 October 2026: hemogenyx.com about, pipeline, investors, announcements and contact pages. The pipeline page's patient count may be out of date; the 2026 announcements (including an April 2026 institutional fundraise) were seen as titles only, so no funding rows are listed.","The pipeline page states blood cancer incidence figures from 2014 and other claims that were not checked; they are not repeated.","Trial facts from the ClinicalTrials.gov record NCT06786533, read on 29 October 2026."],"hq":"London","country":"GB","companyType":"cell-therapy","website":"https://hemogenyx.com/","ticker":"HEMO.L","founded":2013,"stage":"public","investors":[],"funding":[]},"route":"/companies/hemogenyx-pharmaceuticals/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"},{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}]}}